MICHELLE MCDANIEL: Open Payments
NPI 1225489917 · DAVENPORT, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,945 in 185 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $1,373 · 2025 $3,945
Food & beverage: $3,945
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 37 | $816 |
| Otsuka America Pharmaceutical, Inc. | 30 | $543 |
| ABBVIE INC. | 29 | $496 |
| E.R. Squibb & Sons, L.L.C. | 10 | $442 |
| Alkermes, Inc. | 13 | $408 |
| Janssen Pharmaceuticals, Inc | 12 | $261 |
| Teva Pharmaceuticals USA, Inc. | 11 | $258 |
| Supernus Pharmaceuticals, Inc. | 14 | $190 |
| Neurocrine BioSciences, Inc. | 10 | $166 |
| Vanda Pharmaceuticals Inc. | 8 | $142 |
Products named: CAPLYTA, VRAYLAR, COBENFY, ARISTADA, REXULTI, Qelbree, ABILIFY MAINTENA, INGREZZA.
Industry payments across FL — which companies pay providers there.
